Comparison of antiviral efficacy and economics between lamivudine and entecavir in patients with low preoperative HBV replication after liver transplantation
10.3969/j.issn.1006-5725.2015.12.040
- VernacularTitle:恩替卡韦与拉米夫定在术前HBV低复制患者肝移植术后抗病毒疗效及经济学对比
- Author:
Ying WANG
;
Changjie CAI
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Liver transplantation;
Entecavir;
Lamivudine;
HBV reinfection;
Seroconversion
- From:
The Journal of Practical Medicine
2015;(12):2020-2023
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the antiviral efficacy and economics between lamivudine and entecavir in patients with low preoperative HBV replication after liver transplantation. Methods Liver transplantation patients from 2006 July to 2013 July were selected for being studied prospectively. Statistically evaluated between entecavir and lamivudine efficacy by the analysis of postoperative follow-up of seroconversion and HBV reinfection. Results The cumulative overcast rate of entecavir group was 98.04% one month after transplatation. And 3 of 51 cases were reinfected with average turn time of 9.73 days. Meanwhile , the cumulative overcast rate of Lamivudine group was 100% and 3 of 26 cases were reinfected with average turn time of 5.11 days. There are no statistical differences between the two groups accumulation rate , reinfection rates , as well as cumulative infection rates. Conclusion In the cases of low hepatitis B virus replication before liver transplantation, Entecavir and Lamivudine have the similar effect of preventing HBV reinfection after operation. Compared with the cost of Entecavir group, Lamivudine is more economy.
